Adriana Renzoni1, Francisco Perez2, Marie Thérèse Ngo Nsoga2,3, Sabine Yerly1, Erik Boehm1, Angèle Gayet-Ageron4, Laurent Kaiser1,2,3, Manuel Schibler1,3. 1. Laboratory of Virology, Laboratory Medicine Division, Diagnostic Department, Geneva University Hospitals, CH-1211 Geneva, Switzerland. 2. Faculty of Medicine of Geneva, University of Geneva, CH-1211 Geneva, Switzerland. 3. Division of Infectious Disease, Geneva University Hospitals, CH-1211 Geneva, Switzerland. 4. CRC & Division of Clinical-Epidemiology, Department of Health and Community Medicine, University of Geneva & University Hospitals of Geneva, CH-1211 Geneva, Switzerland.
Abstract
Extended community testing constitutes one of the main strategic pillars in controlling the COVID-19 pandemic. Reverse transcription PCR (RT-PCR) targeting the SARS-CoV-2 genome on nasopharyngeal swab samples is currently the reference test. While displaying excellent analytical sensitivity and specificity, this test is costly, often requires a substantial turnaround time, and, more importantly, is subject to reagent and other material shortages. To complement this technology, rapid antigen tests have been developed and made available worldwide, allowing cheap, quick, and decentralized SARS-CoV-2 testing. The main drawback of these tests is the reduced sensitivity when RT-PCR is the gold standard. In this study, we evaluate Visby an innovative, portable, easy-to-use RT-PCR point-of-care (POC) diagnostic device. Our retrospective analysis shows that overall, compared to the Cobas 6800 RT-qPCR assay (Roche), this RT-PCR POC technology detects SARS-CoV-2 RNA with 95% sensitivity (95%CI = 86.3-99%) and 100% specificity (95% CI = 80.5-100%). For samples with cycle-threshold values below 31, we observed 100% sensitivity (95% CI = 66.4-100%). While showing an analytical sensitivity slightly below that of a standard RT-qPCR system, the evaluated Visby RT-PCR POC device may prove to be an interesting diagnostic alternative in the COVID-19 pandemic, potentially combining the practical advantages of rapid antigen tests and the robust analytical performances of nucleic acid detection systems.
Extended community testing constitutes one of the main strategic pillars in controlling the COVID-19 pandemic. Reverse transcription PCR (RT-PCR) targeting the n class="Species">SARS-CoV-2 genome on nasopharyngeal swab samples is currently the reference test. While displaying excellent analytical sensitivity and specificity, this test is costly, often requires a substantial turnaround time, and, more importantly, is subject to reagent and other material shortages. To complement this technology, rapid antigen tests have been developed and made available worldwide, allowing cheap, quick, and decentralized SARS-CoV-2 testing. The main drawback of these tests is the reduced sensitivity when RT-PCR is the gold standard. In this study, we evaluate Visby an innovative, portable, easy-to-use RT-PCR point-of-care (POC) diagnostic device. Our retrospective analysis shows that overall, compared to the Cobas 6800 RT-qPCR assay (Roche), this RT-PCR POC technology detects SARS-CoV-2 RNA with 95% sensitivity (95%CI = 86.3-99%) and 100% specificity (95% CI = 80.5-100%). For samples with cycle-threshold values below 31, we observed 100% sensitivity (95% CI = 66.4-100%). While showing an analytical sensitivity slightly below that of a standard RT-qPCR system, the evaluated Visby RT-PCR POC device may prove to be an interesting diagnostic alternative in the COVID-19 pandemic, potentially combining the practical advantages of rapid antigen tests and the robust analytical performances of nucleic acid detection systems.
Authors: Kuangwen Hsieh; Peter L Mage; Andrew T Csordas; Michael Eisenstein; H Tom Soh Journal: Chem Commun (Camb) Date: 2014-02-28 Impact factor: 6.222
Authors: Ole Behrmann; Iris Bachmann; Martin Spiegel; Marina Schramm; Ahmed Abd El Wahed; Gerhard Dobler; Gregory Dame; Frank T Hufert Journal: Clin Chem Date: 2020-08-01 Impact factor: 8.327
Authors: Victor M Corman; Olfert Landt; Marco Kaiser; Richard Molenkamp; Adam Meijer; Daniel Kw Chu; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Marie Luisa Schmidt; Daphne Gjc Mulders; Bart L Haagmans; Bas van der Veer; Sharon van den Brink; Lisa Wijsman; Gabriel Goderski; Jean-Louis Romette; Joanna Ellis; Maria Zambon; Malik Peiris; Herman Goossens; Chantal Reusken; Marion Pg Koopmans; Christian Drosten Journal: Euro Surveill Date: 2020-01
Authors: Gannon C K Mak; Stephen S Y Lau; Kitty K Y Wong; Nancy L S Chow; C S Lau; Edman T K Lam; Rickjason C W Chan; Dominic N C Tsang Journal: J Clin Virol Date: 2020-12-04 Impact factor: 3.168
Authors: Christopher Greer McCollum; Thomas N Creger; Aadia I Rana; Lynn T Matthews; Stefan D Baral; Greer A Burkholder; William A Curry; Latesha Elopre; Faith E Fletcher; Sydney Grooms; Emily B Levitan; Max Michael; Barbara Van Der Pol; Michael J Mugavero Journal: Am J Public Health Date: 2022-08-11 Impact factor: 11.561
Authors: Karim Kaci; Rafael Del Caño; Mónica Luna; Paula Milán-Rois; Milagros Castellanos; Melanie Abreu; Rafael Cantón; Juan Carlos Galán; Álvaro Somoza; Rodolfo Miranda; Guillermo González de Rivera; Tania García-Mendiola; Encarnación Lorenzo Journal: Talanta Date: 2022-05-18 Impact factor: 6.556
Authors: Maiken W Rosenstierne; Shreya Joshi; E Thomas Danielsen; Helen Webb; Dac Mui Luong; Julie Bjerring; Julie Hindkær; Lærke Jørgensen; Julie Blauenfeldt; Ask Bojesen; Flemming Holck; Johnny Weber Lau; Lars Bangsgaard; Jakob Broberg Lind; Mette Bjergaard Dragheim; Mikkel Rohde Jacobsen; Robert Elkjær; Steven Clauwaert; Kristina Christensen; Charlotta Polacek; Anders Fomsgaard; Tuomas Ojalehto; Antti Tullila; Mirko Brummer; Claus Juel Jensen; Frederikke Holm Jensen; Uffe Vest Schneider; Jan Gorm Lisby; Rikke Lind Jørgensen; Thomas Warthoe; Ebbe Finding; Peter Warthoe Journal: Sci Rep Date: 2021-11-15 Impact factor: 4.379